{
  "emaEpar": [],
  "fdaDrugLabel": [
    {
      "brand": "Unituxin",
      "indication": "1 INDICATIONS AND USAGE Unituxin (dinutuximab) is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy [see Clinical Studies (14) ]. Unituxin is a GD2-binding monoclonal antibody indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. ( 1 )",
      "manufacturer": "United Therapeutics Corporation",
      "splSetId": "d66bdf0d-9d65-45de-ae5b-a58617c27492"
    }
  ],
  "id": "Dinutuximab",
  "nciThesaurus": {
    "casRegistry": "1363687-32-4",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "A chimeric mouse/human monoclonal antibody with potential antineoplastic activity. Dinutuximab binds to the ganglioside GD2 and induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against GD2-expressing tumor cells.  GD2 is overexpressed in malignant melanoma, neuroblastoma, osteosarcoma, and small cell carcinoma of the lung.",
    "fdaUniiCode": "7SQY4ZUD30",
    "identifier": "C1570",
    "preferredName": "Dinutuximab",
    "semanticType": "Amino Acid, Peptide, or Protein",
    "subclassOf": [
      "C155653"
    ],
    "synonyms": [
      "Ch 14.18UTC",
      "Ch14.18",
      "DINUTUXIMAB",
      "Dinutuximab",
      "MOAB Ch14.18",
      "Unituxin",
      "monoclonal antibody Ch14.18"
    ]
  }
}